The rapid evolution of active immunotherapies has transformed the therapeutic landscape, particularly in oncology, where personalized cancer vaccines, neoantigen-based therapies, RNA-based platforms, and other immune-driven approaches are moving from experimental concepts toward commercial reality. Yet as the science has advanced, one persistent regulatory challenge has remained: how can sponsors reliably demonstrate the potency of products whose therapeutic activity depends on complex and highly individualized immune responses?
FDA’s new draft guidance, Potency Assessment of Active Immunotherapy Products, provides the Agency’s most comprehensive perspective to date on this issue. While potency has always been a fundamental requirement for biologics regulated under Section 351 of the Public Health Service Act, this guidance establishes a more structured framework for developing potency strategies for active immunotherapy products (ACTIMPs), including personalized therapies that present unique analytical and manufacturing challenges.
For sponsors, the guidance represents more than a technical discussion about assays. It is a clear signal that FDA expects potency assurance to become an integral part of development strategy from the earliest stages of product development through commercialization.
Why This Guidance Matters Now
Active immunotherapy products differ fundamentally from many traditional biologics. Rather than exerting a direct pharmacological effect, these products work by stimulating, modulating, or directing a patient's immune system to recognize disease-associated antigens. Examples include peptide- and protein-based immunotherapies, vectored immunotherapies, personalized neoantigen therapies, and cell-based antigen-presenting approaches.
This mechanism creates a unique regulatory challenge. Unlike monoclonal antibodies or recombinant proteins, where biological activity can often be measured directly, the potency of active immunotherapies frequently depends on downstream immune responses that occur inside the patient. As a result, establishing meaningful potency assays has historically been one of the most difficult aspects of product development.
FDA acknowledges this reality throughout the guidance, particularly for personalized therapies where each batch may contain patient-specific antigens and where traditional product-specific analytical tools may not be available.
The guidance therefore serves as both a regulatory roadmap and a reflection of how the Agency is adapting its expectations to accommodate the next generation of immunotherapies.
FDA's Core Message: Potency Must Be Linked to Mechanism of Action
Perhaps the most important theme running throughout the document is FDA's emphasis on connecting potency measurement directly to product mechanism of action (MOA).
The Agency recommends that sponsors begin by developing a thorough understanding of how a product is expected to achieve its therapeutic effect and then identify potency-related Critical Quality Attributes (CQAs) that support that mechanism. Potency assays should be designed to measure, directly or indirectly, the product's ability to induce the intended immune response.
This represents a shift from viewing potency as a late-stage analytical requirement toward treating it as a development-wide strategy.
FDA specifically emphasizes that potency-related CQAs should support lot release testing, stability assessments, and comparability evaluations. Moreover, these attributes should be scientifically justified through product characterization data, preclinical evidence, clinical observations, published literature, or a combination of sources.
For sponsors, the implication is clear: potency cannot simply be demonstrated at the end of development. It must be built into the product development program from the beginning.
A Risk-Based and Flexible Approach
One of the more encouraging aspects of the guidance is FDA's recognition that a single potency approach will not work across all active immunotherapies.
The Agency continues to support a science- and risk-based framework that allows considerable flexibility, particularly during early clinical development. FDA recognizes that investigational products may not initially possess fully validated potency assays and endorses a progressive, iterative approach to potency assay development as product understanding evolves.
However, this flexibility comes with an important caveat. FDA notes that inadequate potency data could ultimately place development programs at risk, including the possibility of clinical holds if product quality or patient safety cannot be adequately assessed. Consequently, early engagement with FDA review teams remains strongly encouraged.
For Regulatory Affairs and CMC teams, this reinforces the importance of developing a potency roadmap that matures alongside the product.
Personalized Immunotherapies Receive Long-Awaited Regulatory Clarity
Perhaps the most notable aspect of the guidance is FDA's discussion of personalized immunotherapies, particularly neoantigen-based cancer vaccines and individualized immunotherapy platforms.
Historically, one of the greatest challenges for personalized therapies has been determining how potency should be demonstrated when every manufactured batch is unique. Creating a dedicated bioassay for every individual patient's product is often impractical and potentially impossible from an operational standpoint.
FDA appears to recognize this reality.
For personalized peptide- and protein-based immunotherapies, the guidance outlines circumstances in which physicochemical testing may be sufficient for lot release, provided that sponsors have adequately qualified the overall manufacturing process and justified the use of their bioinformatics pipeline used to identify target antigens.
This may be one of the most consequential aspects of the guidance. Rather than requiring product-specific functional assays for every individualized therapy, FDA is signaling that confidence in process controls, bioinformatics algorithms, and manufacturing qualification may serve as the foundation for potency assurance.
This approach reflects a modern regulatory understanding of personalized medicine and could significantly facilitate development of individualized immunotherapy products.
Bioinformatics Has Officially Become a Regulatory Critical Quality Consideration
An especially important development is FDA's recognition of bioinformatics pipelines as a critical component of product quality and potency.
For therapies that depend on computational identification of patient-specific epitopes, FDA expects sponsors to justify and qualify the bioinformatics process used to select those antigens. The Agency notes that changes to these algorithms or computational workflows may affect product potency, safety, and effectiveness and therefore may require additional assessment and regulatory review.
This is a significant evolution in regulatory thinking.
Historically, analytical methods and manufacturing processes were the primary focus of CMC oversight. FDA is now making it clear that computational systems used to design personalized therapies are becoming equally important components of the control strategy.
Sponsors developing AI-enabled antigen prediction platforms, neoantigen selection algorithms, or personalized vaccine design systems should take particular note.
Implications for Sponsors
From a strategic perspective, the guidance creates several important considerations.
First, potency strategy should no longer be viewed exclusively as a late-stage CMC activity. Instead, it should be incorporated into product development planning from preclinical development onward. Early decisions regarding mechanism of action studies, biomarker characterization, immunogenicity assessments, and manufacturing design may ultimately influence regulatory success.
Second, sponsors should expect greater scrutiny of their rationale for selecting potency-related CQAs. FDA repeatedly emphasizes the need to demonstrate a meaningful relationship between product attributes and therapeutic activity.
Third, companies developing personalized immunotherapies should invest early in validating manufacturing workflows, computational tools, and process controls. Under FDA's framework, robust process qualification may become just as important as traditional biological testing.
Finally, the guidance reinforces the importance of proactive interaction with FDA review teams. Potency expectations are inherently product-specific, and early discussions may help avoid costly development delays later in the program.
Looking Ahead
FDA's draft guidance reflects the maturation of the active immunotherapy field. As cancer vaccines, neoantigen therapies, RNA platform technologies, and personalized immunotherapies continue to advance, the Agency is moving toward a more sophisticated framework for assessing product potency that balances scientific rigor with practical development realities.
The most important takeaway is that potency is no longer simply an analytical endpoint. FDA increasingly views potency assurance as a comprehensive strategy that integrates product characterization, manufacturing controls, bioinformatics, analytical testing, and clinical understanding. Sponsors that embrace this broader perspective early in development will be better positioned to navigate regulatory expectations and accelerate the path toward licensure.
.webp)
